Clear all
2021 • KEYNOTE-365 cohort B: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)–pretreated patients with metastatic castration-resistant prostate cancer (mCRPC)—New data after an additional 1 year of follow-up.

Works in BIP! associated with the specified OpenAIRE research product

Leonard Joseph Appleman, Michael Paul Kolinsky, William R. Berry, Margitta Retz, Loic Mourey, Josep (...)
Journal of Clinical Oncology · 2021
Internal medicine |         Oncology |